Navigation Links
Metastatic pancreatic, primary breast cancer have common growth mechanisms, study suggests
Date:7/11/2013

CINCINNATIA recently discovered form of the protein that triggers blood clotting plays a critical role in promoting the growth of metastatic pancreatic cancer and primary breast cancer, according to the cumulative findings from two new scientific manuscripts published online ahead of print in the International Journal of Cancer and PNAS (Proceedings of the National Academy of Sciences).

The protein, called "Tissue Factor," is present in various tissuesfor example, walls of blood vessels. Earlier studies suggested that alternatively spliced Tissue Factor (asTF) may contribute to cancer growth, but the molecular events leading to this were previously unknown.

New research conducted through an international collaboration between the labs of Vladimir Bogdanov, PhD, of the University of Cincinnati Cancer Institute, and Henri Versteeg, PhD, of the Einthoven Laboratory for Experimental Vascular Medicine at the Leiden University Medical Center in Leiden, the Netherlands, articulates how asTF fuels growth and metastasis of solid cancers.

Using preclinical animal models, Bogdanov and Versteeg's teams obtained the first scientifically validated evidence that asTF promotes the spread of pancreatic cancer and promotes primary growth of breast cancer tumors.

"We have demonstrated that targeting asTF with a novel monoclonal antibodydeveloped based on our 10 years of studying asTFalso stops the growth of breast cancer in an animal model, giving us a promising new target to fight certain forms of breast cancer," says Bogdanov, who originally described asTF in 2003. UC filed a patent for this technology in January 2013.

Bogdanov and Versteeg presented their findings at the XXIV Congress of the International Society on Thrombosis and Haemostasis in Amsterdam, the Netherlands (held June 29-July 4, 2013).

"Many molecules on the surface of cellsincluding integrinsare important for the function of both normal and cancerous cells, so targeting integrins for stopping the growth of cancer is not a promising strategy. What is unique about asTF is that it binds to integrins on vessel-forming cells, activating them. We've shown that certain cancer cells share those same qualities, so if you target asTFwhich is elevated in cancerthere is significant potential to spare the 'good' parts of the cellular system while removing the 'bad' cancer-specific protein from the game," explains Bogdanov.

"Many routine therapies such as chemotherapy or radiation may not always be efficient. Targeting asTF in tumors using our monoclonal antibody may form a potent additional anticancer strategy in combination with conventional avenues", says Versteeg.


'/>"/>

Contact: Amanda Harper
amanda.harper@uc.edu
513-558-4657
University of Cincinnati Academic Health Center
Source:Eurekalert

Related biology news :

1. Mechanism found connecting metastatic breast cancer and arthritis
2. Cancerous tumors deliver pro-metastatic information in secreted vesicles
3. Should high-dose interleukin-2 continue to be the treatment of choice for metastatic melanoma?
4. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
5. Thomas Jefferson University researchers discover new pathways that drive metastatic prostate cancer
6. LSUHSC research discovers new drug target for metastatic breast cancer
7. Modulating the immune system to combat metastatic cancer
8. How cancer spreads: Metastatic tumor a hybrid of cancer cell and white blood cell
9. PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations
10. Commonly used diabetes drug may help to prevent primary liver cancer
11. Biology professor secures grant to save West Virginias primary natural history collection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona combed ... pleural mesothelioma. Their findings are the subject of a new article on the Surviving ... signposts in the blood, lung fluid or tissue of mesothelioma patients that can help ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
Breaking Biology Technology: